Immunity to varicella-zoster virus in patients before and after lung transplantation

Immunity to varicella-zoster virus in patients before and after lung transplantation - VZV and lungTx

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43319

Enrollment

190

Registered

2016-10-10

Start date

2016-05-02

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster shingles

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Provision of written informed consent • >=18 years of age;(for the part evaluating vaccination) • Intended administration of VZV vaccine

Exclusion criteria

Exclusion criteria: • Pregnancy;(for the part evaluating vaccination) • No administration of VZV vaccine due to any reason

Design outcomes

Primary

Measure	Time frame
Cellular immunity is chosen as the primary objective as this measure is known to be more important than humoral immunity in the defence to VZV. Main study endpoint will be changes in cellular immunity pre-vaccination, 2 weeks and 3 months after vaccination, and 3 months after lung transplantation.	—

Secondary

Measure	Time frame
As secondary objectives humoral immunity and control parameters will be determined. Furthermore, herpes zoster incidence will be registered.	—

Countries

Netherlands

Outcome results